Liposomal Peptides

About this video

Seeds answers directly whether liposomal delivery can make a peptide bioavailable enough to match subcutaneous injection, and says no. He argues scepticism is warranted and that such products are not a substitute for injection without extensive validation that sellers typically do not provide. He lists what proof would require: characterising encapsulation, measuring encapsulation efficiency for the specific peptide in its claimed lipid matrix with laboratory methods, showing particle-size distribution and stability over shelf life, and demonstrating release behaviour across stomach, intestinal, and saliva conditions while the peptide stays inside the vesicle. He points to the difficulty the GLP-1 market has had with oral delivery as a reality check.

Key takeaways

• Ask for encapsulation efficiency data for the specific peptide, not generic liposomal claims
• Stability, particle size, and release kinetics all need proof over the product’s shelf life
• If oral delivery were easy, Seeds argues, major drug markets would already have adopted it
• Equivalence to injection is a claim that requires head-to-head evidence

Episode details: published August 31, 2026 · 272 views · 3:00 long. Summary written by Self Growth Videos from the episode itself. The peptide and cellular-medicine concepts described are Dr. William Seeds’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: the SSRP Institute sells clinician certification in peptide therapy.

← Previous: Ep.74 - Girls and Sports Injuries: Is There An Epidemic We’re Not Paying Attention To? · Next: Ep.75 - Alcohol: The Facts About Use and Abuse →

All Dr. William Seeds videos · Dr. William Seeds profile · SSRP Institute (official site)